Grace Therapeutics, Inc.
GRCENasdaq
$2.47
↑ +2.5%Jul 17 close · end-of-day
Price
1Y↓ -26.0%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$40.8M
Enterprise Value
$23.8M
P/E
—
P/S
—
P/B
0.6
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$7.8M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-12.2%
ROIC
-18.6%
Debt / Equity
—
Net Cash
$17.0M
Return 1Y
-26.3%
Company profile
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal betamethasone spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. The company was incorporated in 2002 and is headquartered in Princeton, New Jersey.
- CEO
- Prashant Kohli
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Headquarters
- New Jersey
- Website
- www.gracetx.com
Earnings
GRCE Q4 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.06↓ -154.5%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|
| Revenue | $196,000.00 | $100.0M | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$16.4M | -$15.6M | -$52.2M | -$12.9M | -$16.7M | -$11.1M |
| Net income | -$19.7M | -$9.8M | -$42.4M | -$12.9M | -$9.6M | -$7.8M |
| Diluted EPS | — | -$0.27 | -$5.71 | -$1.35 | -$0.79 | -$0.47 |
| Operating cash flow | -$14.3M | -$17.2M | -$15.9M | -$12.3M | -$14.9M | -$8.9M |
| Free cash flow | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -8377.0% | -15.6% | — | — | — | — |
| Net margin | -10039.8% | -9.8% | — | — | — | — |
| Line item | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '25 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$5.0M | -$4.8M | -$3.7M | -$3.2M | -$3.1M | -$2.5M | -$2.4M | -$3.0M |
| Net income | -$2.6M | -$3.4M | -$4.2M | $636,000.00 | -$3.4M | -$938,000.00 | -$2.3M | -$1.2M |
| Diluted EPS | -$0.24 | -$0.30 | -$0.36 | $0.11 | -$0.21 | -$0.06 | -$0.14 | -$0.06 |
| Operating cash flow | -$3.6M | -$4.2M | -$4.1M | -$3.0M | -$1.8M | -$3.1M | -$2.2M | -$1.7M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Apr 23, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.